The Relationship of 25-Hydroxyvitamin D Plasma Levels with Breast Cancer Stadium Assessed from Menopause Status

Ika Waraztuty¹, Astrid Siska Pratiwi², Melya Susanti³, Ira Astuti¹, Zakirullah⁵
¹Department of Anatomy-Histology, Faculty of Medicine, Universitas Syiah Kuala, Indonesia
²¹,²,³,⁴Postgraduate Program in Biomedical Sciences Faculty of Medicine, Universitas Sumatera Utara, Indonesia
³Anatomy Department, Faculty of Medicine, Universitas Baiturrahmah, Indonesia
⁴Division of Medical Surgical Nursing, Langsa Nursing Study Program, Poltekkes Kemenkes Aceh, Indonesia
Email: ika waraztuty@unsyiah.ac.id

Abstract:
Breast cancer is a type of cancer with high incidence and mortality especially in developing countries. Vitamin D regulates the expression of a number of genes involved in the development of cancer cells. The aim of this study is to analyze the relationship between 25-hydroxyvitamin D (25 (OH) D) plasma level with breast cancer stage based on menopausal status. This is an observational research method with cross sectional design. Research subjects were 53 newly diagnosed breast cancer patients and had not received chemotherapy. Menopausal status and stage data were obtained from interviews and medical record data. Levels of 25-hydroxyvitamin D plasma were measured (ELISA) method. The results obtained Stage II, III and IV each have an average level of vitamin D of 28.56 ng/ml (95% CI; 23.61 – 33.52 ng/ml), 28.18 ng/ml (95% CI; 24.49 – 31.87 ng/ml) and 27.86 ng/ml (95% CI; 22.68 – 33.04 ng/ml). The average plasma concentration of 25 (OH) D in pre-menopausal patients is 28.54 ng/ml and average plasma 25 (OH) D levels in post-menopausal patients is 27.79 ng/ml. There was no significant relationship between plasma levels of 25 (OH) D and breast cancer stage in both pre-menopausal and post-menopausal patients.

Keywords:
25-hydroxyvitamin D; stage of breast cancer; pre-menopause; post menopause

I. Introduction

Breast cancer is the most common type of cancer in women with a high mortality rate. In 2012, there were 522,000 deaths from breast cancer worldwide. In Asia, as many as 639,824 cases of breast cancer were recorded throughout 2012. Countries with the highest number of cases include China (187,213 cases), India (144,937 cases), Japan (55,710 cases), Indonesia (48,998 cases) and Pakistan (34,038 cases). The highest mortality rates are in India, China, Indonesia, Pakistan and Japan. (Bray, F (2013); Ghoncheh, M (2016)).

The risk factor for breast cancer is multifactorial, one of which is nutrition. Vitamin D is a fat-soluble vitamin which has various functions. Low levels of vitamin D are associated with a number of diseases such as diabetes, cardiovascular disease, osteoporosis, multiple sclerosis and cancer. Several case control studies have reported lower levels of vitamin D in breast cancer patients compared to control subjects. (Atoum, M.F (2017); (Elsoud, M.R.A (2016); (Younus A. (2016)).

This is inseparable from the role of vitamin D as an anticancer agent. Research by Jeong et al. in animals, it has been shown that vitamin D can inhibit the growth and development of breast cancer cells. In invitro 1, 25 (OH) 2D (active vitamin D) and its
analogues have antiproliferative activity that can inhibit proliferation and trigger apoptosis cultured breast cancer cells. (Jeong, Y. (2015); Chen, J. (2014); Duffy, MJ. (2016)).

Vitamin D regulates the expression of a number of genes involved in cancer cell development. In the process of proliferation, vitamin D increases the expression of p21 and p27 and decreases the expression of CKDs and cyclin. In the process of apoptosis, vitamin D increases the expression of antiapoptotic proteins. In terms of inhibiting metastasis, vitamin D is able to reduce MMP expression and decrease HIF1α, VEGF, I.18 expression. Several studies have reported lower levels of vitamin D in women who have gone through menopause compared to women who have not. Given the large role of vitamin D in the development of cancer cells, vitamin D deficiency in women who have undergone menopause is a risk factor for breast cancer. On the other hand, exposure to estrogen in breast tissue causes women who have not menopause in the age range 45-55 years to be more at risk for breast cancer. (Capatina, C. (2014); Gaugris, S. (2005); Beral, V. (2012)).

Breast cancer stage is a clinical assessment to describe the size of the cancer, its spread and its effects on other organs based on 3 criteria, namely tumor size, lymph nodes and metastases. Judging from the mechanism of action, vitamin D has an influence on the 3 components that determine these stages. Therefore, researchers wanted to see the relationship between plasma 25-hydroxyvitamin D (25 (OH) D) levels with breast cancer stage based on menopausal status.

II. Research Methods

Based on the inclusion criteria, the subjects in this study were women who were diagnosed with breast cancer and had not undergone chemotherapy. A total of 53 subjects were collected from October 2017 - February 2018 at the surgical Oncology clinic of H. Adam Malik Hospital, Medan.

Subjects were interviewed to determine the characteristics of diagnosed age, age of menarche, menopausal status and age, history of contraceptive use and history of breast cancer, while breast cancer stage data were obtained from patient medical records.

The subject's blood was drawn as much as 3 cc. The blood is inserted into the EDTA tube and the plasma is separated. The plasma is then stored at -80c until the vitamin D levels are checked.

Plasma vitamin D levels were checked by ELISA method using 25-hydroxyvitamin D (25 (OH) D) Kit (® DBC Canada). The inspection protocol follows the instructions on the kit.

2.1 Ethical Clearance

This research was approved by the Health Research Ethics Committee, Faculty of Medicine, University of North Sumatra with letter no 473 / TGL / KEPK FK USU-RSUP HAM / 2017. Before conducting interviews and taking blood, all research subjects signed the informed consent after being given an explanation of the aims and benefits of the study.

2.2 Statistic Analysis

Normality test using Shapiro-Wilk Bivariate analysis using the Spearman rank correlation test ANOVA test to assess differences in mean levels of vitamin D in the group stage and menopausal status. The limit of significance set is 5%.
III. Results and Discussion

3.1 Results

Based on the characteristics of research subjects, it is known that 45.3% of study subjects were in the age range of 40-49 years, 58.5% experienced menarch under 13 years. There were 50.9% patients with post-menopause, and 59.3% with menopausal age 45-50 years, there were 49.1% with a history of hormonal contraceptive use and 17.0% with a family history of breast cancer (Table 1.)

| Characteristics | n (%) |
|-----------------|-------|
| **Age**         |       |
| <40 years       | 6 (11.3) |
| 40-49 years     | 24 (45.3) |
| 50-59 years     | 14 (26.4) |
| 60-69 years     | 7 (13.2) |
| ≥ 70 years      | 2 (3.8) |
| **Menarch's age** |   |
| ≤ 13 years      | 31 (58.5) |
| > 13 years      | 22 (41.5) |
| **Menopause Status** |       |
| Pre-Menopause   | 26 (49.1) |
| Post-Menopause  | 27 (50.9) |
| **Menopausal Age** |   |
| <45 years       | 4 (14.81) |
| 45-50 years     | 16 (59.26) |
| > 50 years      | 7 (25.93) |
| **History of hormonal contraception** |   |
| There is        | 26 (49.1) |
| Not             | 27 (50.9) |
| **Family history** |   |
| There is        | 9 (17.0) |
| Not             | 44 (83.0) |

Table 2. Average Vitamin D Levels based on Cancer Stage and Menopausal Status

| Variable | N | Mean (95% CI) | p  |
|----------|---|---------------|----|
| Cancer Stage |   |               |    |
| I        | 0 | -             | 0.980 |
| II       | 11 | (23.61 - 33.52) |   |
| III      | 25 | (24.49 - 31.87) |   |
| IV       | 17 | (22.68 - 33.04) |   |
Table 3. Relationship between Vitamin D Levels and Cancer Stage Based on Menopausal Status

| Menopause Status | Stadium | Average Vitamin D Levels | P |
|------------------|---------|--------------------------|---|
| Pre Menopause    | I       | -                        |   |
|                  | II      | 25,967                   | 0.185 |
|                  | III     | 30,962                   |     |
|                  | IV      | 26,257                   |     |
| Post Menopause   | I       | -                        |   |
|                  | II      | 30,850                   | 0.721 |
|                  | III     | 26,063                   |     |
|                  | IV      | 28,555                   |     |

* Anova test

Based on the stage of breast cancer, there were no subjects with stage I, 11 subjects with stage II, 25 people with stage III and 17 people with stage IV. Stages II, III and IV each had mean vitamin D levels of 28.56 ng / ml (95% CI: 23.61 - 33.52 ng / ml), 28.18 ng / ml (95% CI: 24.49 - 31.87 ng / ml), 27.86 ng / ml (95% CI: 22.68 - 33.04 ng / ml). There appears to be a decrease in vitamin levels in line with the increase in breast cancer stage, but it is not statistically significant. Based on menopausal status, there were 26 subjects with pre-menopause and 27 subjects with post menopause. There was no significant difference in vitamin D levels between the menopause and postmenopausal groups, namely 28.54 ng / ml (95% CI: 25.84 - 31.24 ng / ml), 27.79 ng / ml (95% CI: 23, 56 - 32.01 ng / ml) (p = 0.758) (Table 2).

Mean vitamin D levels based on breast cancer stage in the pre-menopausal group, II (25.97 ng / ml), III (30.96 ng / ml), IV (26.26 ng / ml) (p = 0.185 > 0.05), and in the post-menopausal group II (30.85 ng / ml), III (26.06 ng / ml), IV (28.55 ng / ml) (p = 0.721 > 0.05). (Table 3). There was no difference in vitamin D levels in the two groups in terms of breast cancer stage.

3.2 Discussion

According to Arysha (2020) women are one important element in a family or community. Therefore, women's health, especially their reproductive health, is one of the important health problems. Vitamin D is widely known to have an immunogenic role and
play an anti-proliferative role in the body as well as an endocrine hormone. Vitamin D deficiency is known to be associated with an increase in the incidence of malignancies from the breast, prostate, and colon (Garland, C.F. 2009). Suboptimal vitamin D levels are assumed to trigger cell proliferation, angiogenesis, and metastasis.

In this study, there were no research subjects with stage I. There was no statistically significant relationship between 25 (OH) D levels in each group of breast cancer stages. However, it is still seen that the higher the stage of the study subject, there is a decrease in 25 (OH) D levels. This study is in line with previous research by Karthikayan et al. who found no significant association between cancer stage and levels of 25 (OH) D (Karthikayan, A. 2018). The most common presentation of breast cancer is a lump in the breast that does not cause pain. Some people tend to ignore this symptom. As a result, patients with an advanced clinical stage are a common occurrence. Because everyone’s health-seeking behavior is different, this is a confounding factor in clinical staging.

Patients with poorly differentiated breast cancer have lower levels of vitamin D (Karthikayan A, 2018) than patients with moderately differentiated and well differentiated tumors. This suggests that true vitamin D metabolites inhibit proliferation and induce apoptosis and cell differentiation.

Physiologically, changes in a woman’s menopausal status are known to have an effect on reducing levels of 25-hydroxyvitamin D (25 (OH) D). This occurs due to changes in diet, lifestyle, insulin sensitivity, and decreased physical activity experienced by menopausal women. In addition, postmenopausal women experience changes in vitamin D metabolism, such as a decrease in the synthesis of vitamin D from the skin or changes in the body’s consumption of vitamin D which affects vitamin D status and body physiology (Perez-Lopez FR, 2020). There is also a hypothesis that the presence of estrogen increases activity of enzymes that play a role in activating Vitamin D, decreased levels of estrogen during the menopause transition can trigger symptoms of Vitamin D deficiency (Buchanan, J.R. 1986).

Several studies evaluating the relationship between vitamin D and breast cancer based on menopausal status are still inconsistent (Shin, MH (2002); Lin, J (2007); Knight, JA (2007); Rossi, M (2009)). In this study there was no significant relationship between 25 (OH) D levels and menopausal status in the study subjects. Although it appears that 25 (OH) D levels are lower in study subjects with post-menopausal status. This study is in line with Karthikayan et al. who found no significant relationship between menopausal status and levels of 25 (OH) D (Karthikayan A, 2018). In addition, it is in line with research conducted by Anderson et al. who found no significant interaction between Vitamin D, calcium or menopausal status (Anderson, L.N. 2010).

Unlike the case-control research conducted by Kawase et al. who found that vitamin D and calcium intake were inversely associated with the development of breast cancer risk in all subjects (pre- and postmenopausal). However, vitamin D intake was significantly associated only with the pre-menopausal group of women, and calcium intake was significantly associated with risk in postmenopausal women. This association has been modified by differences in tumor receptor status. So they concluded that vitamin D and calcium decreased the risk of breast cancer in Japanese women and that this relationship differed based on menopausal status and receptor status (ER, PR, HER2).
In this study, there was no significant relationship between vitamin D levels and breast cancer stage based on the menopausal status of the study subjects. This is in line with other studies which state that there is no significant relationship between low vitamin D levels and tumor prognosticncy (Imtiaz, S. 2014).

However, in contrast to other studies that stated 25 (OH) D levels were significantly higher in patients with early stage cancer compared to those with advanced or metastatic stages (Palmeri, C. 2006). The relationship between vitamin D levels, breast cancer, and prognostic factors such as tumor stage, grade, size, lymphatic node metastasis and status of hormone receptors were contradictory. Low vitamin D levels are associated with advanced stage, tumor size, and grade in patients with post-menopausal status (Janbabai, G. 2016), similarly to women with premenopausal status but triple-negative (Yao, S. 2017). Vitamin D insufficiency and deficiency are found in tumors with advanced stages and metastases, many positive lymph nodes, a low proportion of ER +, PR +, and high Ki-67 (de Sousa Almeida, 2017).

The inconsistency of results across existing studies may be related to different sample sizes and limited demographic information related to ethnicity and lifestyle. Menopausal status may be closely related to vitamin D status and vitamin D receptor polymorphisms. In addition, there is a modified influence of environmental factors, such as diet, gene variations that are closely related to vitamin D metabolic pathways such as vitamin D-binding protein, an enzyme that plays a role in activation and degradation of vitamin D (Atoum, M. 2017).

References

Anderson LN, Cotterchio M, Vieth R, Knight JA. (2010). Vitamin D and calcium intakes and breast cancer risk in pre- and postmenopausal women. Am J Clin Nutr. 91:1699-707.

Arysha, V.O., Santosa, H., and Sanusi, S.R. (2020). The Effect of Extrinsic Motivation on Housewife Actions in IVA Test in the Working Area of Community Health Center at Bandar Kalipah. Britain International of Exact Sciences (BIOEx) Journal Vol. 2 (1):352-356 Atoum M and Alzoughool F. (2017). Vitamin D and Breast Cancer: Latest Evidence and Future Steps. Breast Cancer: Basic and Clinical Research.11: 1-8.

Atoum Manar Fayiz, Yasmeen Mohammad Al Khatib. (2017). Association between serum 25-hydroxy vitamin D concentration and Taq1 vitamin D receptor gene polymorphism among Jordanian females with breast cancer. Chinese Medical Journal. 30 (9): 1074-1078.

Beral V, Bull D, Pirie K, Reeves G, et al. (2012). Menarche, menopause and breast cancer risk: individual participant meta-analysis, including 118964 women with breast cancer from 117 epidemiological studies. 13 : 1141-1151.

Bray F, Ren JS, Masuyer E, Ferlay J. (2013). Global estimate of cancer prevalence for 27 site in adult population in 2008. International J Cancer. 32(5): 1133-1145.

Buchanan JR, Santen R, Cauffman S, Cavaliere A, Greer RB, Demers LM. (1986). The effect of endogenous estrogen fluctuation on metabolism of 25-hydroxyvitamin D. Calcif Tissue Int. 39(3): 139-44.

Capatina C, Carsote M, Carageorgheopol A, Poiana C, et al. (2014). Vitamin D deficiency in postmenopausal women- biological correlates. Journal of Clinical Medicine. 9(4): 316-322.
Chen J, Wang J, Kim TK, Tieu EW, Tang EK, Lin Z, et al. (2014). Novel Vitamin D Analog as potential therapeutics: The metabolism, toxicity profiling ad antiproliferative activity. Anticancer Res. 34(5): 2153-2163.

Deeb Kristin K, Trump Donald L, Johnson Candace S. (2007). Vitamin D signaling pathway in cancer: Potential for Anticancer Therapeutics. Nature Review Cancer. 7: 684-700.

de Sousa Almeida-Filho B, De Luca Vespoli H, Pessoa EC, Machado M, Nahas-Neto J, Nahas EAP. (2017). Vitamin D deficiency is associated with poor breast cancer prognostic features in postmenopausal women. J Steroid Biochem Mol Biol. 174:284–289.

Duffy MJ, Murray A, Synott NC, Donovan N, John Crown. (2016). Vitamin D analogues: potential use in cancer treatment. Critical Review in Oncology/Hematology. 112: 190-197.

Elsoud Moustafa R Abo, Ali H.Abu Syam, Soheir R Demian and Basma H.Mersal. (2016). Study of relationship between vitamin D receptor gene polymorphism expression (Bsm I & Fok I), serum Level of Vitamin D and the risk breast cancer in Egyptian female; correlation with clinicopathological features of the disease. Int J of Basic and Applied Medical Sciences. 6 (2) :89-99.

Garland CF, Gorham ED, Mohrb SB, Garland FC. (2009). Vitamin D for cancer prevention: global perspective. Ann Epidemiol.19(7):468-83.

Gaugris S, Heaney RP, Boonen S, Kurth H. (2005). Vitamin D inadequacy among postmenopausal women: a systematic review. QJ Medicine. 98 : 667-676.

Ghoceneh M, Mahdavifar N, Darvishi E, Salehiniya H. Epidemiology, incidence and mortality of breast cancer in Asia. Asian Pacific Journal Cancer Prevention. (2016). 17: 47-52.

Holick MF. (2004). Vitamin D: Importance in the prevention of cancers, type 1 diabetes, heart diseases and osteoporosis. The American Journal of Clinical Nutrition 79 (3): 362-371.

Imtiaz S, Siddiqui N. (2014). Vitamin-D status at breast cancer diagnosis: correlation with social and environmental factors and dietary intake. J Ayub Med Coll Abbottabad. 26:186–190.

Imtiaz S, Siddiqui N, Raza SA, Loya A, Muhammad A. (2012). Vitamin D deficiency in newly diagnosed breast cancer patients. Indian J Endocrinol Metab.16(3): 409-13.

James SY, Mackay AG, Colston KW. (1996). Effects of 1, 25 dihydroxyvitamin D3 and its analogues on induction of apoptosis in breast cancer cells. J Steroid Biochem Mol Biol. 58(4): 395-401.

Janbabai G, Shekarriz R, Hassanzadeh H, Aarabi M, Borhani SS. (2016). A survey on the relationship between serum 25-hydroxy vitamin D level and tumor characteristics in patients with breast cancer. Int J Hematol Oncol Stem Cell Res. 10:30–36.

Jeong Y, Swami S, Krisnan AV, Williams JD, Martin S, Horst RS, et al. (2015). Inhibition of mouse breast tumor initiating cell by calcitriol and dietary vitamin D. Molecular Cancer Therapy. 14(8): 1951-1961.

Kawase T, Matsum K, Suzuki T, Hirose K, Hosono S, Watanabe M, Inagaki M, Iwata H, Tanaka H, Tajima K. (2010). Association between vitamin D and calcium intake and breast cancer risk according to menopausal status and receptor status in Japan. Cancer Sci. 101(5): 1234-1240.

Knight JA, Lesosky M, Barnett H, Raboud JM, Vieth R. (2007). Vitamin D and reduced risk of breast cancer: a population-based case-control study. Cancer Epidemiol Biomarkers Prev. 16:422–9.
Lin J, Manson JE, Lee IM, Cook NR, Buring JE, Zhang SM. (2007). Intakes of calcium and vitamin d and breast cancer risk in women. Arch Intern Med. 167:1050–9.
Palmieri C, MacGregor T, Girgis S, Vigushin D. (2006). Serum 25-hydroxyvitamin D levels in early and advanced breast cancer. J Clin Pathol. 59:1334–1336.
Perez-Lopez FR, Chedraui P, Pilz S. (2020). Vitamin D Supplementation after menopause. Ther Adv Endocrinol Metab. 11: 1-13.
Pratiwi AS & Siregar Y. (2018). Hubungan Kadar Vitamin D Plasma dengan Indeks Mitosis pada Pasien Kanker Payudara. Sriwijaya Journal of Medicine. 1(3): 143-149.
Rossi M, McLaughlin JK, Lagiou P, et al. (2009). Vitamin D intake and breast cancer risk: a case-control study in Italy. Ann Oncol. 20:374–8.
Shin MH, Holmes MD, Hankinson SE, Wu K, Colditz GA, Willett WC. (2002). Intake of dairy products, calcium, and vitamin d and risk of breast cancer. J Natl Cancer Inst. 94:1301–11.
Subramanian P, Oranye NO, Masri AM, Taib NA, Ahmad N. 2013. Breast cancer knowledge and screening behavior among women with a positive family history: a cross sectional study. Asian Pac J Cancer Prev. 14(11): 6783-90.
Waraztuty I, Siregar KB, Siregar Y. 2018. Vitamin D Receptor Gene TAQ 1 (rs 731236) Polymorphism in Breast Cancer Patients at H Adam Malik Hospital Medan and Its Relationship with Histopathology grading. Biomed J Sci & Tech Res. 6(1): 5031-5035.
Waraztuty I, Siregar Y, Siregar KB, Wanandi SI, Betty B. 2020. Polymorphism of Vitamin D Receptor Gene Taq 1 (rs 731236) Associated with Plasma Vitamin D Group Levels Among Breast Cancer Patients in H. Adam Malik Hospital, Medan. J Pharm Biomed Sci. 10(02):19-26.
Yao S, Kwan ML, Ergas IJ, et al. 2017. Association of serum level of vitamin D at diagnosis with breast cancer survival: a case-cohort analysis in the pathways study. JAMA Oncol. 3:351–357.
Younus Amna, Faiz Mariam, Yasmeen Abida. 2016. Serum vitamon D in women with pre/post menopausal newly diagnosed breast cancer in Pakistan. Journal of Food and Nutrition Research. 4 (12) : 828-833.